Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
122.27
+3.72 (3.14%)
Oct 9, 2026, 2:27 PM EDT - Market open
Corcept Therapeutics Market Cap
Corcept Therapeutics has a market cap or net worth of $13.22 billion as of October 9, 2026. It is the 1,759th most valuable company in the world and the 632nd biggest in the United States. Its market cap has increased by 41.84% in one year.
Market Cap
13.22B
Enterprise Value
12.68B
1-Year Change
41.84%
Global Rank
Country Rank
#632 United States
Category
ChartMarket Cap Chart
Since April 14, 2004, Corcept Therapeutics's market cap has increased from $283.00M to $13.22B, an increase of 4,570.19%. That is a compound annual growth rate of 18.63%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 13.22B | 261.06% |
| Dec 31, 2025 | 3.66B | -30.67% |
| Dec 31, 2024 | 5.28B | 57.69% |
| Dec 29, 2023 | 3.35B | 53.13% |
| Dec 30, 2022 | 2.19B | -4.35% |
| Dec 31, 2021 | 2.29B | -24.78% |
| Dec 31, 2020 | 3.04B | 119.78% |
| Dec 31, 2019 | 1.38B | -10.36% |
| Dec 31, 2018 | 1.54B | -25.15% |
| Dec 29, 2017 | 2.06B | 155.69% |
| Dec 30, 2016 | 806.10M | 48.81% |
| Dec 31, 2015 | 541.70M | 78.43% |
| Dec 31, 2014 | 303.60M | -5.24% |
| Dec 31, 2013 | 320.40M | 124.53% |
| Dec 31, 2012 | 142.70M | -50.47% |
| Dec 30, 2011 | 288.10M | 3.11% |
| Dec 31, 2010 | 279.40M | 60.85% |
| Dec 31, 2009 | 173.70M | 248.10% |
| Dec 31, 2008 | 49.90M | -59.17% |
| Dec 31, 2007 | 122.20M | 336.43% |
| Dec 29, 2006 | 28.00M | -66.22% |
| Dec 30, 2005 | 82.90M | -41.54% |
| Dec 31, 2004 | 141.80M | -49.89% |
| Apr 14, 2004 | 283.00M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascendis Pharma | 15.06B |
| Jazz Pharmaceuticals | 15.00B |
| Exelixis | 14.35B |
| Summit Therapeutics | 13.68B |
| BridgeBio Pharma | 13.03B |
| Halozyme Therapeutics | 12.42B |
| Madrigal Pharmaceuticals | 11.45B |
| Bio-Techne | 11.36B |